Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell Cancer

Clinical trial NCT06067776 · NOT_YET_RECRUITING

Trial details

NCT number: NCT06067776
Sponsor: Jonathan Riess
Status: NOT_YET_RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Metastatic Lung Non-Small Cell Carcinoma Recurrent Lung Non-Small Cell Carcinoma Stage IV Lung Cancer AJCC v8

Start date: 2024-01-01
Primary completion: 2025-01-01
Enrollment: 36

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.